《痰热清注射液治疗社区获得性肺炎随机对照试验的系统分析.doc》由会员分享，可在线阅读，更多相关《痰热清注射液治疗社区获得性肺炎随机对照试验的系统分析.doc（3页珍藏版）》请在三一办公上搜索。
1、痰热清注射液治疗社区获得性肺炎随机对照试验的系统分析文章来源 毕业论文网 毕业论文 【摘要】 评价痰热清注射液治疗社区获得性肺炎（communityacquired pneumonia, CAP）的疗效和安全性。方法：收集痰热清注射液治疗CAP随机对照试验文献，纳入的文献按不同治疗策略进行分层，Jadad计分表评价纳入文献的质量，对纳入的试验作系统评价。 结果：符合纳入标准的论文共12篇。Meta分析结果显示，痰热清与抗生素联合治疗组与抗生素治疗组相比，治愈率相对危险度（relative risk, RR）为1.51，95%可信区间（confidence interval, CI）
2、1.29，1.77；显效率RR为1.31，95% CI 1.20，1.43；有效率RR为1.17，95% CI 1.11，1.23。退热时间加权均数差（weighted mean difference, WMD）为1.24，95%CI 1.71，0.76；咳嗽和咳痰显效率RR分别为1.42和1.27，95% CI 1.16，1.74和1.04，1.55；胸片阴影吸收RR为1.19，95%CI 1.09，1.30；中性粒细胞下降RR为1.10，95% CI 1.03，1.17。两组上述各指标比较，差异均有统计学意义。未报道痰热清注射液临床应用相关的严重不良反应。 结论：现有临床证据表明在抗生素及
3、对症治疗基础上给予痰热清注射液治疗CAP可以明显提高临床疗效，并明显改善咳嗽咳痰症状，缩短发热时间，促进胸片阴影的吸收和血象恢复，未见明显的不良反应。由于纳入研究质量所限，尚需开展更多高质量的研究进一步分析。 论文网 毕业论文【关键词】 痰热清注射液; 社区获得性肺炎; 随机对照试验; 系统评价; meta分析 Jiang HL, Mao B, Zhong YQ, Yang HM, Fu JJ. J Chin Integr Med. 2009; 7(1): 919. Received July 30, 2008; accepted Se
4、ptember 9, 2008; published online Jaunary 15, 2009. Indexed/abstracted in and full text linkout at PubMed. Journal title in PubMed: Zhong Xi Yi Jie He Xue Bao. Free full text (HTML and PDF) is available at . Forward linking and reference linking
5、via CrossRef. DOI: 10.3736/jcim20090102Open Access Tanreqing Injection for communityacquired pneumonia: a systematic review of randomized evidence Hongli JIANG, Bing MAO, Yunqing ZHONG, Hongmei YANG, Juanjuan FU Department of In
6、tegrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China Objective: To evaluate the efficacy and safety of Tanreqing Injection, a compound traditional Chinese herbal medicine, for communityacquired pneumonia
7、. Methods: Literatures about randomized controlled trials of Tanreqing Injection for communityacquired pneumonia were reviewed. Related literatures were selected and analyzed according to different treatment strategies of the trials. The methodological quality of the trials was ass
8、essed by the Jadad scale, and evaluation was performed. Results: Twelve randomized controlled trials meeting the inclusion criteria were selected and reviewed. As Tanreqing combined group (Tanreqing Injection plus antibiotics and basic therapy) was compared with antibiotics group (
9、antibiotics plus basic therapy), the metaanalysis indicated that the relative risk (RR) for the total cure rate was 1.51, and 95% confidence interval (CI) was 1.29, 1.77; RR for the total obvious effect rate was 1.31, and 95% CI was 1.20，1.43; RR for the effective rate was 1.17, and 95% CI was 1.11,
10、 1.23. The weighted mean difference (WMD) in disappearance time of fever between the two groups was 1.24, and 95% CI was 1.71, 0.76. The RR values between the two groups for the total obvious effect rate of cough and expectoration were 1.42 and 1.27, and 95% CIs were 1.16, 1.74 and 1.04, 1.55 respec
11、tively. The RR values between the two groups in absorption of chest Xray shadow and neutrophil number were 1.19, 1.10 and 95% CIs were 1.09, 1.30, 1.03, 1.17 respectively. The differences were all statistically significant. Serious systematic adverse reactions had not been reported in the trials.&nb
12、sp; Conclusion: The effect of combined therapy with Tanreqing Injection plus antibiotics and basic therapy is better than that of antibiotics plus basic therapy. Tanreqing Injection can improve the symptoms of cough and expectoration, shorten the fever time and facilitate the absorption
13、of chest Xray shadow, without any significant adverse reactions. However, further highquality trials are needed. Keywords: Tanreqing Injection; communityacquired pneumonia; randomized controlled trials; systematic review; metaanalysis 肺炎是内科常见病、多发病，是指终末气道、肺泡和间质的炎症。
14、按感染的场所不同，分为社区获得性肺炎（communityacquired pneumonia, CAP）和医院获得性肺炎。CAP是指在医院外罹患的感染性肺实质炎症，包括具有明确潜伏期的病原体感染而在入院后平均潜伏期内发病的肺炎。美国每年约有300万560万CAP患者1，超过100万人次住院，近1 000万人次就医，直接医疗花费在84亿97亿美元2，3。 从中医角度来讲，CAP属于中医学风温肺热、咳嗽和喘证等范畴。患者常因感受外邪而致痰湿化热，出现咳嗽、痰量增加、咯痰黄稠、发热、舌苔黄厚或腻、脉滑数等痰热阻肺的临床症状，痰热阻肺证为CAP的主要证候之一，治宜清肺化痰、止咳平喘。自20世纪70年代开始在西医治疗基础上运用清热化痰中药治疗CAP以来，越来越多的研究结果显示在西医治疗基础上运用清热化痰类方剂较单纯西医治疗更有优势，清热化痰已成为中西医结合治疗CAP的主要方法之一。目前痰热清方为治1
